ArticleBritish journal of cancer2022
Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study.
Article in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Correlation of Computed Tomography (CT)-Based Body Composition and Survival in Pancreatic Cancer Patients: A Systematic Review.Tomography (Ann Arbor, Mich.) · 2026Pooled it
- Diagnostic Risk Prediction Models for Upper Gastrointestinal Cancers: A Systematic Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Pooled it
- Relationship between pancreatic cancer resection rate and survival at population level: systematic review.BJS open · 2025Pooled it
- Epidemiology of Cancer in Older Adults: A Systematic Review.Current oncology reports · 2024Pooled it
- Review
- Microbiome-pancreatic cancer crosstalk: From tumor biology to therapeutic intervention.iMetaOmics · 2026Review
- Harmonization Framework for Translating Clinical Cancer Staging Systems for Public Health and Surveillance Use in Low- and Middle-Income Countries: Validation Using Indian Cancer Registry Data.Cancer medicine · 2026Article
- Recent survival trends in the most fatal cancers in the Nordic countries: gains in some but not in all.Acta oncologica (Stockholm, Sweden) · 2026Article
- Exosomal miR-92a-3p promotes pancreatic cancer cells' extravasation by inducing vascular permeability through inhibition of DAB2IP.Cell death & disease · 2026Article
- Temporal Trends in Pancreatic Cancer in New South Wales, Australia: A Longitudinal Population-Based Study of Incidence, Surgery and Survival.ANZ journal of surgery · 2026Article
- Clinical characteristics of programmed death-1 inhibitors for older patients with advanced pancreatic cancer.World journal of gastrointestinal oncology · 2026Article
- Persistence of severe global inequalities in the burden of pancreatic cancer: a cross-sectional study.Discover oncology · 2026Article
- HRASLS2 promotes the growth and glycolysis of pancreatic cancer by enhancing the stability of ASPH.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Impact of concomitant use of renin-angiotensin system inhibitors on survival in patients with pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Therapeutic advances in medical oncology · 2026Article
- Targeting SERPINB3-MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy.Molecular cancer · 2025Article
- DNA methylation-mediated ADA overexpression drives pancreatic cancer progression.Discover oncology · 2025Article
- DeepOptimalNet: optimized deep learning model for early diagnosis of pancreatic tumor classification in CT imaging.Abdominal radiology (New York) · 2025Article
- Burden of pancreatic cancer among the Western Pacific Region and association with human resources for health from 1990 to 2021: Results from the Global Burden of Disease Study 2021.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Recent Advances in Nanotechnology-Based Approaches for Ferroptosis Therapy and Imaging Diagnosis in Pancreatic Cancer.Pharmaceutics · 2025Review
- Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.Cancer biology & medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe global burden of pancreatic cancer has steadily increased, while the prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the stage- and age-specific pancreatic cancer net survival (NS) for seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom.
methodsThe study included over 35,000 pancreatic cancer cases diagnosed during 2012-2014, followed through 31 December 2015. The stage- and age-specific NS were calculated using the Pohar-Perme estimator.
resultsPancreatic cancer survival estimates were low across all 7 countries, with 1-year NS ranging from 21.1% in New Zealand to 30.9% in Australia, and 3-year NS from 6.6% in the UK to 10.9% in Australia. Most pancreatic cancers were diagnosed with distant stage, ranging from 53.9% in Ireland to 83.3% in New Zealand. While survival differences were evident between countries across all stage categories at one year after diagnosis, this survival advantage diminished, particularly in cases with distant stage.
conclusionThis study demonstrated the importance of stage and age at diagnosis in pancreatic cancer survival. Although progress has been made in improving pancreatic cancer prognosis, the disease is highly fatal and will remain so without major breakthroughs in the early diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.